Molecular typing is based on molecular genetic tests and isn't but routinely readily available. Molecular subtypes and immunohistochemical surrogate markers of your tumors (HR, HER2, triple destructive) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and